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Abstract
Background: Intermittent preventive treatment in infants (IPTi) has been shown to decrease clinical malaria by approximately
30% in the first year of life and is a promising malaria control strategy for Sub-Saharan Africa which can be delivered alongside
the Expanded Programme on Immunisation (EPI). To date, there have been limited data on the cost-effectiveness of this
strategy using sulfadoxine pyrimethamine (SP) and no published data on cost-effectiveness using other antimalarials.
Methods: We analysed data from 5 countries in sub-Saharan Africa using a total of 5 different IPTi drug regimens; SP,
mefloquine (MQ), 3 days of chlorproguanil-dapsone (CD), SP plus 3 days of artesunate (SP-AS3) and 3 days of amodiaquine-
artesunate (AQ3-AS3).The cost per malaria episode averted and cost per Disability-Adjusted Life-Year (DALY) averted were
modeled using both trial specific protective efficacy (PE) for all IPTi drugs and a pooled PE for IPTi with SP, malaria incidence,
an estimated malaria case fatality rate of 1.57%, IPTi delivery costs and country specific provider and household malaria
treatment costs.
Findings: In sites where IPTi had a significant effect on reducing malaria, the cost per episode averted for IPTi-SP was very
low, USD 1.36–4.03 based on trial specific data and USD 0.68–2.27 based on the pooled analysis. For IPTi using alternative
antimalarials, the lowest cost per case averted was for AQ3-AS3 in western Kenya (USD 4.62) and the highest was for MQ in
Korowge, Tanzania (USD 18.56). Where efficacious, based only on intervention costs, IPTi was shown to be cost effective in
all the sites and highly cost-effective in all but one of the sites, ranging from USD 2.90 (Ifakara, Tanzania with SP) to USD
39.63 (Korogwe, Tanzania with MQ) per DALY averted. In addition, IPTi reduced health system costs and showed significant
savings to households from malaria cases averted. A threshold analysis showed that there is room for the IPTi-efficacy to fall
and still remain highly cost effective in all sites where IPTi had a statistically significant effect on clinical malaria.
Conclusions: IPTi delivered alongside the EPI is a highly cost effective intervention against clinical malaria with a range of
drugs in a range of malaria transmission settings. Where IPTi did not have a statistically significant impact on malaria,
generally in low transmission sites, it was not cost effective.
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Introduction
Malaria continues to devastate lives: 247 million malaria cases
were reported among 3.3 billion people at risk in 2006 mostly in
sub-Saharan Africa, and mostly in children under five [1]. One
promising prevention strategy is intermittent preventive treatment
of malaria in infancy (IPTi), which involves delivering treatment
doses of an antimalarial drug at specified times during routine
Expanded Programme on Immunization (EPI) visits, regardless of
Plasmodium infection status [2,3].
PLoS ONE | www.plosone.org 1 June 2010 | Volume 5 | Issue 6 | e10313A pooled analysis of data from 6 completed trials of IPTi with
sulfadoxine-pyrimethamine (SP) demonstrated 30% (20%; 39%)
protective efficacy (PE) against clinical malaria, 38% (13%; 56%)
PE against hospitalisations with malaria parasites, 23% (10%;
34%) PE against all-cause hospital admissions and 21% (8%; 33%)
PE against anaemia in the first year of life[4]. Two further IPTi
studies used drugs other than SP. In northern Tanzania, IPTi with
mefloquine (MQ) was shown to reduce episodes of malaria in
infants in a moderate transmission setting (PE 38%)[5], but had no
protective effect against other outcomes including anaemia and
hospital admission. Neither IPTi with SP nor 3 days of
chlorproguanil-dapsone (CD3) were efficacious in this site. In
western Kenya the PE of SP plus 3 days of artesunate (SP-AS3)
and 3 days of amodiaquine-artesunate (AQ3-AS3) were 22% and
25% respectively against all episodes of malaria during the first
year of life [6]. Three days of CD had no significant protective
effect in this site either.
In addition to the efficacy of IPTi, the costs associated with
introducing and successfully delivering the intervention as part of
an integrated health system have been studied in detail [7], as have
the policy implications of introducing and sustaining the delivery
of IPTi [2,8,9] and the perceptions of the communities who have
received IPTi[10,11]. To date, there has only been one evaluation
of the cost-effectiveness of delivering IPTi, in Ifakara, Tanzania
and Manhica, Mozambique, which showed IPTi to be highly cost-
effective in both settings, at under USD12 per Disability-Adjusted
Life-Year (DALY) averted [12].
In this paper, we report on the cost-effectiveness of IPTi across
all IPTi clinical trial study sites in sub-Saharan Africa, spanning
nine sites in five countries using five different drug regimens.
Methods
Ethics Statement
The study was approved by the ethical committees of the
various research institutes associated with this work. After
obtaining written, informed consent, data on malaria treatment
costs were collected from the families of children involved in the
study. In an attempt to assess the resource use and associated costs
of treating children with malaria from the health facility
perspective, written or verbal consent was sought from the health
care professionals before they were interviewed, or observed,
depending on site specific requirements. Verbal consent was
considered sufficient for health care workers in certain sites as the
socio economic analysis came at the end of the wider efficacy
study, therefore facility staff had a history of working with those in
the study and were already sensitized to the aims and objectives of
the cost effectiveness sub-study.
Study Settings
Table S1 offers an overview of the characteristics of the IPTi
studies included in the economic analysis. Costing data was
collected in association with all the trials. More detailed
explanations of the study characteristics can be found elsewhere:
Ifakara, southern Tanzania [13], Manhica, Mozambique [14],
Lambare ´ne ´, Gabon [15], Korogwe in Tanga region and Same in
Kilimanjaro region, northern Tanzania[5] western Kenya [6] and
the 3 Ghanaian sites Tamale [16], Kumasi [17] and Navrongo
[18]. For the 3 Ghanaian IPTi studies the costs were associated
with treating infant inpatient and outpatient malaria collected
alongside a seasonal IPT for children trial in Ghana [19]. The
same economist and costing methodology were used in Ghana as
in this analysis.
Effectiveness Data
Local conditions and logistical considerations led to slight
differences in the methods used to detect clinical outcomes of
interest across the studies, however, in general, similar and
therefore comparable effectiveness outcomes were collected across
the sites. The cost-effectiveness ratios presented include cost per
malaria episode averted and cost per Disability-Adjusted Life-Year
(DALY) averted [20,21,22]. DALYs averted are calculated by
combining burden of disease averted from less malaria morbidity
(as a function of malaria incidence, length of disease, and impact
on quality of life) and less malaria mortality (as a function of
malaria incidence, case fatality rate (CFR) and country specific
average life expectancy at age one year [23]). In this analysis, to
estimate the potential DALYs averted an assumed base CFR from
malaria in infants of 1.57% was taken from a recent epidemio-
logical model based on field data [24,25] used in a previous cost-
effectiveness analysis (CEA) of IPTi [12]. DALYs were calculated
excluding age weighting, using a 3% discount rate and the
disability weights given in the Global Burden of Disease study
[26]. Table S2 summarises the effectiveness and health seeking
inputs.
Costings
The Cost Effectiveness Working Group (CEWG) was part of the
IPTi Consortium and responsible for coordinating the collection
and/or analysis of primary cost data in Kisumu, Korogwe, Same,
Lambare ´ne ´, Manhica, Ifakara and Mtwara. All costs are presented
in 2007 USD.
Costs of intervention. The costs of the intervention were
based on a detailed costing of IPTi delivery in Mtwara, southern
Tanzania where 13,976 infants were given IPTi over the course of
2 years as part of a phased implementation study delivering IPTi
within routine health services across five districts [8]. A breakdown
of the cost per dose of delivering SP in Mtwara is given elsewhere
[7]. Costs included national and district costs associated with:
policy change; community sensitization; behaviour change and
communication; drug purchase and distribution; training;
administration of IPTi in health facilities and management. The
integration of IPTi delivery into the existing health system
structures and functions varied by site. For example in Gabon
the dispensing of IPTi was undertaken in the research centre
separate from the main health facilities, whereas in western
Kenya, IPTi was distributed with EPI vaccinations on a daily basis
in dispensaries, health centers, and the outpatient department of a
mission hospital. For the purposes of this paper, the costs of
delivering IPTi in Mtwara were adapted to the various different
study sites to represent the cost of delivering IPTi in operational
circumstances and not one generated in more artificial trial
conditions. In the cost analysis of the Mtwara study, international
drug prices were used [7], whereas in this analysis the SP and CD
drug prices from the local or national government central medical
stores were available and therefore used. The costs of SP-AS, AQ-
AS and MQ were identified on the International Drug Price
Indicators List [27] or a joint UN Agencies price list [28]. Both
tradable and non tradable components of the cost of delivering
IPTi were adjusted to USD 2007. USD inflation rates were used
for the tradable component (drug costs). The non tradable
components of the unit costs (for example resources associated
with community sensitisation and training) were adjusted based on
international dollar differences using purchasing power parity
(PPP) adjustment rates, to work out the international dollar
equivalent of buying the same amount of goods and services
outside Tanzania [29].
CEA of IPTi in SSA
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economic costs to providers of treating malaria were based on
detailed retrospective cost data from health facilities across the
study sites between 2006 and 2007. A standardised costing
template was used in all the sites to record resource use associated
with personnel, materials and supplies, equipment, transport,
utilities and buildings. Costings were undertaken at primary,
secondary and tertiary level health facilities. Costs were identified
using information found in patient folders, facility stock records,
activity data collected as part of health information measurements
systems, discussions with health facility personnel (both medical
and administrative) and components of the IPTi study budgets. A
standard ingredients approach was used which involved costing
the quantity used and the value of each unit of input needed to
provide an inpatient or outpatient visit to treat malaria [30,31].
Household costs associated with malaria treatment. Costs
incurred at the household level were collected through structured
exit interviews. These wereadministered to caretakers of children as
they left health facilities after an inpatient or outpatient visit which
had been categorised as malaria. A minimum of 150 inpatient and
150 outpatient interviews were conducted in each CEWG site. All
participants gave informed consent. We gathered data on both
indirect and direct costs incurred by patients’ families. Direct costs
included out-of-pocket expenses such as hospital fees, as well as
expenditure on items such as food and transport. Drugs prescribed
to treat malaria were identified using a mixture of data from the exit
interviews and records of study patients who had visited inpatient or
outpatient care. These drugs were then costed using cost schedules
identified at the district hospital pharmacy and the district health
directorate store. Care was taken to correctly categorise which drug
costs were borne by the provider and which by the household.
Indirect costs included salary lost as a result of time caring for a sick
child at home, traveling to hospital, and the time spent at the facility
while the infant in their care was receiving treatment. Table S3
summarises cost inputs.
Cost-effectiveness model
The approach presented in this paper is based on the model
used by Hutton et al. in their CEA of IPTi in Ifakara, Tanzania
and Manhic ¸a, Mozambique [12]. Three factors account for the
slightly different incremental cost-effectiveness ratios (ICERs) in
this analysis compared to those in Hutton et al. In this analysis we
used slightly different (i) hospitalisation rates (ii) treatment seeking
behaviour estimates and (iii) provider and household costs due to
more recent cost estimates for Ifakara and inflation for Manhica. A
reference target population of 1000 immunized infants were the
base for calculating the aggregate effect of the IPTi intervention.
This was then divided by the estimated aggregate cost of providing
the intervention to give the ICERs, reflecting the IPTi intervention
compared to current practice without IPTi.
Two types of data were used to estimate cost per case averted.
The first was based on cost and efficacy data taken directly from
each of the trials to reflect the intervention period. Table S1
outlines the variation in timing and number of IPTi doses across
the trials. We used the incidence of malaria as measured in the
placebo arm of each trial. In trials using SP, a second set of
ICERs used the costs from each trial that were associated with
delivering all IPTi doses up to twelve months of age, and the
efficacy results of the pooled analysis of these 6 trials [4]. The
combined estimate using random effects meta-analysis of 30.3%
reflected the PE of IPTi-SP against all clinical episodes of malaria
up to one year based on data from Manhica, Lambare ´ne ´, Ifakara,
Navrongo, Kumasi and Tamale. The site-specific incidences of
malaria up to 12 months of age presented as part of the pooled
analysis were also used [4]. In both site-specific and pooled
analyses, the cost savings to the public health system were based
on site-specific (western Kenya, Same, Korogwe) or country-
specific (Manhica, Lambare ´ne ´, Ifakara, Navrongo, Kumasi and
Tamale.) estimates of the proportion of children under the age of
five years, with suspected episode of malaria, who access
government facilities. Severe episodes of malaria were based on
the incidence of hospital admission with malaria parasites
presented in the pooled analysis for SP sites and site specific
publications for non SP IPTi [32]. It was not possible to find an
exact definition of severe malaria that was common among the
trials and therefore a proxy of hospital admission with malaria
parasites was used. We recognise that this is unlikely to strictly
equal severe malaria because causality is not evaluated. However
this was used in the absence of better data. This assumption
influences the cost savings to providers and households and it is
not an input used to determine the ICERs based on intervention
costs. Table S2 presents these inputs.
Results are presented from four perspectives: (1): gross
intervention costs: total IPTi intervention costs, (2) net intervention
costs: health system costs savings due to less malaria treatment
seeking at government health facilities are subtracted from gross
intervention costs (3) total societal direct cost savings: direct patient
cost savings due to less malaria treatment and; (4) total societal
indirect cost savings: household cost savings associated with a
reduction in loss of productivity when caring for a sick child due to
less malaria treatment.
Uncertainty. ICERs were calculated as probability distribu-
tions rather than as point estimates. Ranges used for the input
variables were calculated in different ways and triangular
distributions were assigned [33]. When available, the original
trial data confidence intervals were used, as for the PE. Ranges for
the CFR (1% to 3%), malaria incidence and IPTi intervention
costs are based on the range variability as represented in Hutton et
al. [12]. In sites where provider costs were not available, range
variability from western Kenya was used. In sites where ranges of
household costs (both direct and indirect) were not available, the
range variability of Lambare ´ne ´ was used. These two sites were
used as they had the widest cost variation. In Lambare ´ne ´ direct
and indirect household savings ranges were estimated with
bootstrapping techniques. Bootstrapping involves repeatedly
taking random samples with replacement from a sample dataset
in order to estimate the population statistics of the original sample
[34,35,36]. Where ranges were unavailable we assumed the range
to be of 25% less and more of the average value, specifically the
proportion of children under 5 years of age with malaria accessing
health facilities and rates of hospitalization with malaria parasites.
Threshold analysis. The point at which an intervention
becomes cost effective remains debatable. The selection of cost-
effectiveness thresholds in published literature is subjective [37].
Recent studies have used a multiple of per capita Gross National
Income (GNI) and Gross Domestic Product (GDP)
[38,39,40,41,42]. For this analysis we take the most conservative
cut-off of USD 36 to reflect a highly cost-effectiveness intervention,
and from USD 36 to USD 202 to reflect a cost effective
intervention. As explained by Shillcutt and others [37] these
thresholds are based on estimates by the World Bank in 1993 to
recommend a minimum care package of services in low and
middle income countries [43], and again in 1996 in an effort to
define research priorities [44]. The committees specified USD150
per DALY as ‘attractive’ cost effectiveness and USD25 per DALY
as ‘highly attractive’ cost effectiveness for low-income countries.
For the purposes of our analysis these two thresholds where then
inflated to their 2007 equivalent of USD 202 and USD 36 [45].
CEA of IPTi in SSA
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Seek simulation (Palisade @Risk add-in tool to Microsoft
Excel) to estimate at what level key input variables (IPTi
efficacy, CFR, malaria incidence and cost per dose of IPTi
delivered) cease to be highly cost effective (USD36). Threshold
levels were stochastically estimated over 1000 simulations by
varying all input parameters within the ranges assigned. The
Pearson correlation coefficients, calculated on the simulations,
present the magnitude of the relation between ICERs (in terms of
DALYs averted) and the main parameters that determine them.
The higher the coefficient (in absolute value) the more influence
the variable has on the overall ICER. As the CFR is a major driver
in DALY calculations and because precise site specific CFR were
not available a further univariate sensitivity analysis was
undertaken to assess their influence on the ICERs.
Results
Gross Intervention Costs
Table S4 presents the costs and cost savings associated with
delivering IPTi. Gross intervention costs reflect the economic cost
of delivering IPTi per 1000 infants, having taken into account site-
specific drop out rates. The cost of the dose is largely determined
by the cost of the drug. The cost of delivery of IPTi with SP in trial
settings to 1000 infants ranged from USD 353 in Ifakara,
Tanzania to USD 496 in Navrongo, Ghana. The alternative IPTi
drug regimens cost more as the drugs cost more than SP, ranging
from USD 1244 to deliver AQ3-AS3 in western Kenya to USD
4207 to deliver CD3 in Korogwe and Same, Tanzania.
Net Intervention Costs
The net intervention costs (Table S4) reflect the savings to the
formal health system due to less malaria inpatient and outpatient
visits after accounting for the cost of delivering IPTi. Among the
sites that had a statistically significant impact on reducing malaria,
site specific analysis shows that there are health system cost savings
in Ifakara (all the confidence intervals are highly negative which
signifies that in all circumstances modeled the public health system
benefits from cost savings), cost savings are likely in Navrongo and
there is a reduction in health system costs in the other sites. When
using the efficacy data from the individual trials and the IPTi-SP
pooled analysis, all sites indicate health system cost savings or no
increase of health system costs. Where IPTi did not have a
statistically significant impact on malaria episodes (Lambare ´ne ´,
Korogwe and Same using SP, western Kenya, Korogwe and Same
using CD3, and Same using MQ), IPTi is likely to increase health
system costs as malaria cases may not fall but there is the
additional cost of the intervention. Same, Tanzania had a very low
transmission, 10 fold less than predicted, therefore this trial arm
was stopped early and was under-powered to detect a significant
PE. The additional cost to the health system is most stark when the
more expensive non-SP drugs are used and do not show a
significant reduction in malaria.
Cost Savings to Households
Household cost savings, both direct and indirect, show the
potential societal economic impact of IPTi (Table S4). Results
show that in study sites where IPTi has a statistically significant
impact on malaria, considerable direct savings are made at the
household level, ranging from USD 77 in Manhica with SP to
USD 780 in western Kenya with AQ3-AS3 per 1000 infants.
Indirect cost savings ranging from USD 91 in Tamale with SP to
USD 1468 in western Kenya AQ3-AS3 per 1000 infants. Where
IPTi was not shown to have a significant PE against malaria these
savings will not be seen.
The Cost Per Malaria Episode Averted
In sites where IPTi had a statistically significant effect on
reducing malaria, the cost per episode averted for IPTi-SP is very
low, USD 1.36–4.03 based on trial specific data and USD 0.68–
2.27 based on the pooled analysis, see Table S4. For non SP IPTi,
the lowest cost per case averted is USD 4.62 in western Kenya
with AQ3-AS3 and the highest is Korowge with MQ at USD
18.56.
The Costs Per DALY Averted
In sites where IPTi had a significant effect on reducing malaria,
IPTi is highly cost-effective using SP (i.e. under USD 36 per DALY
averted). In western Kenya, both AS3 IPTi drug combinations are
highly cost effective, although AQ3-AS3 is more cost effective than
SP+AS3. In Korogwe MQ is cost effective at USD 39.63 per
DALY averted, see Table S4.
Threshold and correlation analysis
Table S5 shows (for each site in which IPTi showed a
statistically significant PE) at which levels of PE, CFR, incidence
of malaria and intervention unit cost (this largely reflects the drug
cost), that IPTi ceases to be a highly cost-effective intervention. In
most of the cases, especially for the epidemiological/clinical factors
(PE, incidence of malaria and CFR), the threshold of USD 36 per
DALY averted is not reached within the ranges of each variable
and according to the level of accuracy required for the calculation.
The analysis shows, for instance, that in Kumasi, if the PE of SP
dropped to 8%, the ICER would be USD 7.68 per DALY averted
(actual threshold). In Manhica a drop of the CFR to 1% would
lead to an ICER of USD 18.72, or if the incidence of malaria
dropped to 0.09 the ICER would increase to USD 16.41.
The threshold simulation further shows that, apart from in
Korogwe (with MQ), the cost of delivery of IPTi across the settings
could increase considerably and still be highly cost effective. For
instance, in the case of Navrongo, there would need to be an
increase to USD 1.52 per dose delivered using site specific data
and USD 1.92 per dose using data from the IPTi-SP pooled
analysis, before IPTi stopped being highly cost effective; the actual
cost is USD 0.13 per dose. IPTi using alternative antimalarials to
SP is closer the threshold of USD 36. Alternative drugs are much
more expensive than SP.
Summarizing the results from Table S5 shows that the clinical
and epidemiological variables (PE, incidence of malaria and CFR),
affect CE ratios much more than intervention costs.
Table S6 shows (i) the level of the CFR at which the
intervention is no longer highly cost-effective, even if outside 1–
3% range used in the PSA and (ii) the value of the ICERs if the
CFR is set at the extremely low level of 0.1%. In most cases the
intervention would be highly cost-effective even with a CFR as low
at 0.35%. The IPTi SP trials in Ifakara, Kumasi, Navrongo and
Tamale, would be borderline highly cost-effective with a CFR as
low as 0.1%.
Discussion
In studies where IPTi was shown to have a statistically
significant impact on reducing malaria, it was cost effective in all
sites with all drugs and highly cost effective in all but one site that
used MQ. As mentioned previously, the thresholds that have been
used in the literature to determine highly cost effective
interventions and cost-effectiveness interventions vary. In this
CEA of IPTi in SSA
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cost effective in the majority of studies. Had we chosen the WHO
threshold of under 16Gross Domestic Product per capita, all of
the studies that had a statistically significant impact on malaria
would have been considered well within the highly cost effective
range [46].
Although not part of this analysis, if we were to add the benefits
of the additional health gains and subsequent cost savings from
averting anaemia and those associated with averting the non-
malaria admissions included in ‘all-cause’ hospitalisations (here we
included only hospital admissions with parasitaemia), the ICERS
would be even more cost effective. For example, IPTi with SP was
not seen to have a statistically significant impact on clinical malaria
in the trial in Gabon. This was due to a number of reasons,
including a steady decline in the malaria incidence in Lambare ´ne ´
area over the past decade (unpublished data), the high mobility of
the local population and a study design with a close-knit passive
and active follow-up system that led to the creation of an
outstandingly healthy study cohort [15]. However, Lambare ´ne ´ did
show a 26% (0%, 45%) PE against moderate anaemia in the first
year of life, the benefits of which are not measured in this analysis.
Cost effectiveness analysis aims to inform policy makers on the
cost-effectiveness associated with different interventions when
decisions have to be made about where to allocate limited funds.
However, caution should be exercised when comparing the cost-
effectiveness of different malaria control strategies [12] as there
needs to be an understanding of site specific epidemiological and
health system characteristics, the costing perspective and how
different malaria control strategies complement and/or substitute
one another. With this in mind, delivery cost of IPTi was between
USD 0.13 (per dose of SP in southern Tanzanian and Ghana) to
USD 1.92 (per dose of CD at 3 days each dose in northern
Tanzania). Other malaria prevention strategies have reported
annual costs (also adjusted to USD 2007) of providing insecticide
treated nets (ITNs) of USD 1.40–USD 3.85 [47], USD 3.42–USD
5.83 for indoor residual household spraying [48], USD 1.94 to
deliver IPT to school children (3 doses, SP & AQ3) [49], and USD
2.60 when delivering a full course of IPT to pregnant women (2
doses, IPTp-SP) via community care and USD2.30 via health
centres [50].
The incremental benefit of IPTi in addition to ITN use needs to
be explored further [51]. In the sites included in this analysis ITN
ownership and use varied. For example in western Kenya, ITNs
were provided alongside the timing of IPTi, thus the PE of IPTi
was in the context of high ITN use [6], whereas in Manhica ITN
use was zero at the time of the study [14].
The potential impact of IPTi on the EPI needs careful
consideration: will it overburden EPI activities and lead to
inequities [52,53] or conversely will the additional benefits of
IPTi provide extra resources and momentum that will strengthen
the EPI and increase vaccination uptake? The level of EPI
coverage will also impact the ICERs as there are certain fixed costs
that remain constant regardless of EPI coverage and the
subsequent number of IPTi doses given (such as communication
and sensitisation materials and a minimum number of training
workshops) and certain variable costs that are related to coverage
(such as IPTi drugs dispensed).
For the multi-dose IPTi drug regimens used in western Kenya,
Korogwe and Same, additional costs were incurred delivering day
two and three doses to achieve maximal efficacy. In a bid to reflect
effectiveness rather than trial efficacy the costs of research staff
used as adherence monitors were excluded from this analysis. It is
important to recognise that there is likely to be a gap between trial
efficacy and programmatic effectiveness for multi-day regimens.
The threshold analysis shows the scope for additional IPTi delivery
costs associated with monitoring adherence or a potential fall in
protective efficacy if day two and three IPTi doses are not taken.
For example, in western Kenya the threshold analysis presented in
Table S5 shows that the PE of IPTi with SP-AS3 could fall from
the trial level of 22% to 9% and from 25% to 10% with AQ3-AS3
and still remain highly cost effective. Alternatively, the IPTi cost
per dose would need to increase from USD 0.60 to 1.33 with SP-
AS3 and USD 0.44 to 1.64 with AQ3-AS3 before it was no longer
highly cost effective. The costs and effects of using community
health workers to prompt caretakers to administer IPTi doses in
days 2 and 3 of multi dose IPTi regimens still need to be evaluated.
Every effort was made to conduct a rigorous analysis, but some
limitations remain. Costing the intervention was a challenge as we
had to extrapolate data from Mtwara, Tanzania to other settings
and countries. The use of PPP adjustments is a recognised
approach [29], but it would have been advantageous to look at
cost variation across sites using primary data. However, the other
sites in our analysis were randomized control trials and therefore it
would not have been possible to measure real system delivery
costs. Cost variation, within and across countries, has important
implications for planning health services and budgets, however
there is surprisingly little data published on this topic [54]. A
within-country cost and cost-effectiveness analysis of nationwide
school-based helminth control in Uganda showed substantial
variation between six districts in the cost per individual treated
(USD0.41–USD0.91)[55]. Hutton and others investigated varia-
tion of maternity costs in Thailand and Cuba in the context of
multicountry, multicentre randomised controlled trials. Unit costs
per antenatal visit and per pregnancy showed considerable
variation, due largely to staffing patterns and productivity [56].
Across 5 Sub-Saharan African countries, the annualized economic
costs per ITN distributed varied from USD2.75 in Togo to
USD8.05 in Senegal [57], explained mainly by differences in the
composition of each programme, levels of existing resources and
spare capacity.
The implications of cost variation for decision making depend
critically on the cost-effectiveness thresholds applied [58]. By
undertaking a threshold analysis, using a particularly conservative
threshold of US$36, we were able to show that the cost per dose of
IPTi, especially IPTi-SP, could vary, more specifically increase
considerably, and still remain highly cost effective across most of
the settings.
To be consistent with Hutton et al (2009) DALYs were
calculated with no age weighting, however we recognize that the
debate on the use of age weighting continues [59,60]. Supporters
of age weighting suggest all societies have age-based biases when
deciding resource allocation. Detractors suggest DALYs can be
criticized on equity grounds as every year of life is of equal value a
priori, and on empirical grounds as the standard age weights may
not accurately reflect social values.
All the ICERs presented in this analysis reflect the PE during
the intervention period and using the pooled IPTi-SP PE. The
analysis does not present the potential cost implications of an
increase in drug resistance which is likely to lead to other health,
health system and household costs [61,62]. The threshold analysis
presented here shows that there is room for the PE to fall and still
remain highly cost effective in all sites where IPTi had a
statistically significant effect on clinical malaria.
While IPTi is shown to be low cost and highly cost effective in
this analysis, this does not guarantee that it will be adopted as a
strategy. The funding of the intervention is vital and given the
scarce resources and competing interventions (malaria and non-
malaria related) countries may recognise the advantages of
CEA of IPTi in SSA
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advantages of delivering IPTi is that it relies on an existing, well
established delivery strategy such as the EPI scheme that already
reaches a high proportion of the target IPTi recipients across all
malarious countries.
Given the limited public health expenditure in many low
income countries, decision makers need cost-effectiveness data to
prioritise potential interventions for scale-up. This analysis shows
that in many settings IPTi is a highly cost effective intervention,
and that IPTi-SP would remain highly cost effective even if the
level of PE of the intervention or the malaria incidence or the CFR
were to decline. IPTi benefits from an already existing delivery
system, EPI, which is a routine point of contact for many infants,
making IPTi potentially one of the most cost effective malaria
interventions available in areas where malaria transmission is
moderate to high.
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